Hypoxia Impairs Muscle Function and Reduces Myotube Size in Tissue Engineered Skeletal Muscle. 2017

Neil R W Martin, and Kathyrn Aguilar-Agon, and George P Robinson, and Darren J Player, and Mark C Turner, and Stephen D Myers, and Mark P Lewis
School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK.

Contemporary tissue engineered skeletal muscle models display a high degree of physiological accuracy compared with native tissue, and therefore may be excellent platforms to understand how various pathologies affect skeletal muscle. Chronic obstructive pulmonary disease (COPD) is a lung disease which causes tissue hypoxia and is characterized by muscle fiber atrophy and impaired muscle function. In the present study we exposed engineered skeletal muscle to varying levels of oxygen (O2 ; 21-1%) for 24 h in order to see if a COPD like muscle phenotype could be recreated in vitro, and if so, at what degree of hypoxia this occurred. Maximal contractile force was attenuated in hypoxia compared to 21% O2 ; with culture at 5% and 1% O2 causing the most pronounced effects with 62% and 56% decrements in force, respectively. Furthermore at these levels of O2 , myotubes within the engineered muscles displayed significant atrophy which was not seen at higher O2 levels. At the molecular level we observed increases in mRNA expression of MuRF-1 only at 1% O2 whereas MAFbx expression was elevated at 10%, 5%, and 1% O2 . In addition, p70S6 kinase phosphorylation (a downstream effector of mTORC1) was reduced when engineered muscle was cultured at 1% O2 , with no significant changes seen above this O2 level. Overall, these data suggest that engineered muscle exposed to O2 levels of ≤5% adapts in a manner similar to that seen in COPD patients, and thus may provide a novel model for further understanding muscle wasting associated with tissue hypoxia. J. Cell. Biochem. 118: 2599-2605, 2017. © 2017 The Authors. Journal of Cellular Biochemistry Published by Wiley Periodicals, Inc.

UI MeSH Term Description Entries
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D009124 Muscle Proteins The protein constituents of muscle, the major ones being ACTINS and MYOSINS. More than a dozen accessory proteins exist including TROPONIN; TROPOMYOSIN; and DYSTROPHIN. Muscle Protein,Protein, Muscle,Proteins, Muscle
D010100 Oxygen An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration. Dioxygen,Oxygen-16,Oxygen 16
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D000070584 Tripartite Motif Proteins A protein family defined by the presence of three ZINC FINGER domains, one of which is a RING FINGER DOMAIN, a coiled-coil region, and a highly variable C-terminal region. They function in many cellular processes including APOPTOSIS and CELL CYCLE regulation. RBCC Protein,TRIM Protein,Tripartite Motif Protein,RBCC Protein Family,RBCC Proteins,TRIM Protein Family,TRIM Proteins,Family, RBCC Protein,Family, TRIM Protein,Motif Protein, Tripartite,Motif Proteins, Tripartite,Protein Family, RBCC,Protein Family, TRIM,Protein, RBCC,Protein, TRIM,Protein, Tripartite Motif,Proteins, RBCC,Proteins, TRIM,Proteins, Tripartite Motif
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015687 Cell Hypoxia A condition of decreased oxygen content at the cellular level. Anoxia, Cellular,Cell Anoxia,Hypoxia, Cellular,Anoxia, Cell,Anoxias, Cell,Anoxias, Cellular,Cell Anoxias,Cell Hypoxias,Cellular Anoxia,Cellular Anoxias,Cellular Hypoxia,Cellular Hypoxias,Hypoxia, Cell,Hypoxias, Cell,Hypoxias, Cellular
D044767 Ubiquitin-Protein Ligases A diverse class of enzymes that interact with UBIQUITIN-CONJUGATING ENZYMES and ubiquitination-specific protein substrates. Each member of this enzyme group has its own distinct specificity for a substrate and ubiquitin-conjugating enzyme. Ubiquitin-protein ligases exist as both monomeric proteins multiprotein complexes. Ubiquitin-Protein Ligase,E3 Ligase,E3 Ubiquitin Ligase,Ubiquitin Ligase E3,Ubiquitin-Protein Ligase E3,Ligase E3, Ubiquitin,Ligase E3, Ubiquitin-Protein,Ligase, E3,Ligase, E3 Ubiquitin,Ligase, Ubiquitin-Protein,Ligases, Ubiquitin-Protein,Ubiquitin Ligase, E3,Ubiquitin Protein Ligase,Ubiquitin Protein Ligase E3,Ubiquitin Protein Ligases
D044843 SKP Cullin F-Box Protein Ligases A subset of ubiquitin protein ligases that are formed by the association of a SKP DOMAIN PROTEIN, a CULLIN DOMAIN PROTEIN and a F-BOX DOMAIN PROTEIN. SCF Ubiquitin Ligase,SCF(Fbw7) Ubiquitin Ligase,SCF(beta-TrCP) Ubiquitin Ligase,SKP1-Cullin Ubiquitin Ligases,Skp1-Cullin-1-F-box Ubiquitin Ligase,Skp1-Cullin-F-Box Proteins,Ligase, SCF Ubiquitin,Ligase, Skp1-Cullin-1-F-box Ubiquitin,Ligases, SKP1-Cullin Ubiquitin,SKP Cullin F Box Protein Ligases,SKP1 Cullin Ubiquitin Ligases,Skp1 Cullin 1 F box Ubiquitin Ligase,Skp1 Cullin F Box Proteins,Ubiquitin Ligase, SCF,Ubiquitin Ligase, Skp1-Cullin-1-F-box,Ubiquitin Ligases, SKP1-Cullin
D048429 Cell Size The quantity of volume or surface area of CELLS. Cell Volume,Cell Sizes,Cell Volumes,Size, Cell,Sizes, Cell,Volume, Cell,Volumes, Cell

Related Publications

Neil R W Martin, and Kathyrn Aguilar-Agon, and George P Robinson, and Darren J Player, and Mark C Turner, and Stephen D Myers, and Mark P Lewis
October 2017, Journal of cellular physiology,
Neil R W Martin, and Kathyrn Aguilar-Agon, and George P Robinson, and Darren J Player, and Mark C Turner, and Stephen D Myers, and Mark P Lewis
January 2016, Cells, tissues, organs,
Neil R W Martin, and Kathyrn Aguilar-Agon, and George P Robinson, and Darren J Player, and Mark C Turner, and Stephen D Myers, and Mark P Lewis
January 2021, Frontiers in physiology,
Neil R W Martin, and Kathyrn Aguilar-Agon, and George P Robinson, and Darren J Player, and Mark C Turner, and Stephen D Myers, and Mark P Lewis
May 1979, Journal of anatomy,
Neil R W Martin, and Kathyrn Aguilar-Agon, and George P Robinson, and Darren J Player, and Mark C Turner, and Stephen D Myers, and Mark P Lewis
December 2014, Journal of cellular biochemistry,
Neil R W Martin, and Kathyrn Aguilar-Agon, and George P Robinson, and Darren J Player, and Mark C Turner, and Stephen D Myers, and Mark P Lewis
October 2005, Journal of applied physiology (Bethesda, Md. : 1985),
Neil R W Martin, and Kathyrn Aguilar-Agon, and George P Robinson, and Darren J Player, and Mark C Turner, and Stephen D Myers, and Mark P Lewis
February 2014, Endocrinology,
Neil R W Martin, and Kathyrn Aguilar-Agon, and George P Robinson, and Darren J Player, and Mark C Turner, and Stephen D Myers, and Mark P Lewis
April 2011, Journal of applied physiology (Bethesda, Md. : 1985),
Neil R W Martin, and Kathyrn Aguilar-Agon, and George P Robinson, and Darren J Player, and Mark C Turner, and Stephen D Myers, and Mark P Lewis
August 2007, Critical care medicine,
Neil R W Martin, and Kathyrn Aguilar-Agon, and George P Robinson, and Darren J Player, and Mark C Turner, and Stephen D Myers, and Mark P Lewis
September 2014, Experimental biology and medicine (Maywood, N.J.),
Copied contents to your clipboard!